ty-jour t1-一线卡铂加上刺皮素，并在患有晚期非Quamous非小无小细胞肺癌的HIV阳性患者中具有刺激性维护：II IIFCT-1001 CHIVA试验JF-欧洲呼吸杂志 - 欧洲呼吸杂志JO-EUR RESSIR JO-EUR RESSIR J DO- 10.1183/13993003.02066-2019 VL - 56 IS - 2 SP - 1902066 AU - Lavole, Armelle AU - Greillier, Laurent AU - Mazières, Julien AU - Monnet, Isabelle AU - Kiakouama-Maleka, Lize AU - Quantin, Xavier AU - Spano，Jean Philippe au -Lena，Herve au -Fraisse，Philippe au -Janicot，Henri au -Audigier -Valette，Clarisse au -Langlais，Alexandra au -Morin，Franck au-弗兰克·澳，麦金岛 - 麦金森，Alain au -cadranel，jacranel，jacques a2 -y1 -y1- y1-，y1 -y1-，y1-，y1-，y1-，y1 -y1-，y1-，y1-，y1-，y1-，y1-，y1-，y1-，y1-，y1-，y1-，y1-，y1-，Y1-，，，地，2020/08/01 UR -http：//www.qdcxjkg.com/content/56/2/2/2/1902066.Abstract N2- HIV感染是肺癌试验中的排除标准。这项多中心II期试验旨在评估一线卡铂和pemetrexed（CAP）的可行性，功效和安全性，然后在患有艾滋病毒（PLHIV）患者（PLHIV）的患者中进行pemetrexed（p）维护NS-NSCLC）。在Eastern合作肿瘤学组绩效状态≤2的患者中，CAP的四个CAP循环进行了p维护治疗。主要目的是12周后疾病控制率（DCR）≥30％。入学的61个PLHIV，49（80％）的性能状态为0-1，19（31％）的脑转移。中位CD4淋巴细胞计数为418个细胞·µL -1（范围18-1230），中位CD4淋巴细胞NADIR为169.5细胞·µl -1（1-822）；48（80％）患者受病毒控制。38名患者（62％）患者实现了四个周期诱导，而31（51％）开始p维护（中值4.1个周期（范围1-19））。12周的DCR为50.8％（95％CI 38.3-63.4），部分响应率为21.3％。 Median progression-free survival and overall survival were 3.5 (95% CI 2.7–4.4) and 7.6 months (5.7–12.8), respectively. Patients with a performance status of 0–1 had the longest median progression-free survival (4.3 months, 95% CI 3.1–5.2) and overall survival (11.9 months, 95% CI 6.4–14.3). During induction, CaP doublet was well tolerated apart from grade 3–4 haematological toxicities (neutropenia 53.8%; thrombocytopenia 35.0%; anaemia 30.0%). Two fatal treatment-related sepses were reported. No opportunistic infections were experienced.In PLHIV with advanced NS-NSCLC, first-line four-cycle CaP induction followed by P-maintenance was effective and reasonably well-tolerated. Further studies should evaluate combination strategies of CaP with immunotherapy in PLHIV.In this first clinical trial dedicated to people living with HIV and advanced non-squamous non-small cell lung cancer, first-line 4-cycle carboplatin plus pemetrexed followed by pemetrexed maintenance chemotherapy was effective and reasonably well-tolerated https://bit.ly/2xAqeEl ER -